Table 3.
Adverse events
| Total cohort | Neratinib monotherapy | Neratinib with capecitabine | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Grade 3–4 haematological AEs | 2 (3) | 0 (0) | 2 (4) |
| Grade 3–4 non-haematological AEs | 13 (18) | 7 (26) | 6 (13) |
| Any grade of diarrhoea | 46 (64) | 18 (67) | 28 (62) |
| Grades of diarrhoea | |||
| 1 | 27 (38) | 12 (44) | 15 (33) |
| 2 | 12 (17) | 4 (15) | 8 (18) |
| 3 | 7 (10) | 2 (7) | 5 (11) |
| Dose reduction | 17 (24) | 4 (15) | 13 (29) |
| Dose delaysa | 34 (47) | 13 (48) | 21 (47) |
AE Adverse event
aDose delay on at least one occasion